MIT and Novo Nordisk researchers have developed a capsule that lets patients receive medications without injections. MIT News ...

Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...

Novo Nordisk continues to witness strong growth across its portfolio of diabetes and obesity care medications. The company's tailwinds include expanded indications and new geographic markets.

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

The needle device market is forecast to grow to over $6.8bn by 2033, according to analysis by GlobalData. Novo Nordisk’s investor relations manager David Heiberg Landsted confirmed the current ...

The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of Denmark after cashing in on the weight-loss drug boom. The Novo Nordisk ...